ArticleAsian Pacific journal of cancer prevention : APJCP2024
Long-Term Effect of TIMP3 Gene Expression on Thyroid Cancer: A Cure Model Analysis.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Integrative Bioinformatics Approach to Investigating TIMP3 and Immune Cell Infiltration: Prognostic and Clinicopathological Implications.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer is the most common endocrine malignancy. TIMP3, a metalloproteinase inhibitor, can inhibit angiogenesis, invasion, and metastasis in thyroid cancer. In this study, we investigated the long-term effect of TIMP3 gene expression and other associated factors on the survival rate and cure probability of thyroid cancer patients.
methodsIn this historical cohort study, clinical information was collected from 507 thyroid cancer patients and 59 control samples based on the TCGA database. The Kaplan-Meier curve and log-rank test were employed for group comparisons. Weibull mixture and non-mixture cure models were utilized to explore the association between TIMP3 gene expression and survival time, as well as cure status. All statistical analyses were conducted using the R language.
resultsThere were 507 thyroid cancer patients and 59 normal tissue participants in the study with an average age of 47.93±15.96 and 47.06 ± 17.74 years respectively. A total of 26.8 percent of patients were male, 69.6 percent had high expression, and 3.16 percent died during the study. Compared with normal tissue participants, tumor-positive patients had significantly lower TIMP3 expression (p<0.001). After 2,000 days of follow-up, 78 percent of patients were cured based on Kaplan-Meier curves. The results show that the Weibull mixture cure model is superior to the non-mixture cure model. Moreover, after controlling for other factors, higher TIMP3 expression was associated with an increased chance of long-term recovery in patients. Specifically, the odds of cure in patients with higher TIMP3 expression were approximately 2.3 times greater than others.
conclusionsTIMP3 expression has a protective effect on cure probability in thyroid cancer patients, even though it does not appear to affect short-term survival. This study suggests that targeting TIMP3 may offer promise for thyroid cancer and may be a potential biomarker for thyroid cancer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.